Ionis Subsidiary Akcea Encouraged By Safety Data In FCS

Phase III data showing statistically significant reduction of triglycerides will bolster the pivotal data expected early next year. Akcea is not concerned by the study’s 20% dropout rate because there were no discontinuations in a subset of patients with FCS.

Awaiting data from its pivotal APPROACH trial during the first quarter of 2017, Akcea Therapeutics was encouraged by safety and efficacy data unveiled Dec. 19 for lead candidate volanesorsen from a separate Phase III study in patients with severe hypertriglyceridemia, including a subset of patients with familial chylomicronemia syndrome (FCS).

Akcea, a subsidiary of antisense-focused Ionis Pharmaceuticals Inc., hopes to file volanesorsen for FCS in 2017 and plans a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Sanofi/Orano Look To Next Steps After Phase II Radiotherapy Success

 

The companies announced positive Phase II results for AlphaMedix, a lead 212-based alpha emitter therapy for gastroenteropancreatic neuroendocrine tumors.

Psoriasis Submissions Iin The Bag, J&J Advances Icotrokinra Into Phase III For Ulcerative Colitis

 
• By 

The company has presented the full set of positive results from the Phase IIb ANTHEM-UC trial in the inflammatory bowel disease.

Hope Medicine Ready To Bring Potential First-in-Class Endometriosis Treatment Into Phase III

 

The non-hormonal drug could be a big step forward in treating pain associated with the condition, but the Chinese company may still need a partner for its Phase III studies and eventual commercialization.

Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups

 
• By 

With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.

More from R&D

Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups

 
• By 

With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.

Ribomic Positions Itself As Latest Potential Achondroplasia Competitor

 

The company announced positive Phase II data for umedaptanib pegol and plans to move it into Phase III development in fiscal year 2026.

Peter Marks Brings Genetic Medicines Street Cred To Lilly

 

FDA’s former CBER director is joining industry as senior VP of molecule discovery and head, infectious disease at Eli Lilly.